JOP20190224A1 - عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي - Google Patents
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعيInfo
- Publication number
- JOP20190224A1 JOP20190224A1 JOP/2019/0224A JOP20190224A JOP20190224A1 JO P20190224 A1 JOP20190224 A1 JO P20190224A1 JO P20190224 A JOP20190224 A JO P20190224A JO P20190224 A1 JOP20190224 A1 JO P20190224A1
- Authority
- JO
- Jordan
- Prior art keywords
- tils
- immunotherapy
- processes
- production
- same
- Prior art date
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000011109 contamination Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000010034 metabolic health Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Abstract
غير متوفر
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478506P | 2017-03-29 | 2017-03-29 | |
US201762539410P | 2017-07-31 | 2017-07-31 | |
US201762548306P | 2017-08-21 | 2017-08-21 | |
US201762554538P | 2017-09-05 | 2017-09-05 | |
US201762559374P | 2017-09-15 | 2017-09-15 | |
US201762567121P | 2017-10-02 | 2017-10-02 | |
US201762577655P | 2017-10-26 | 2017-10-26 | |
US201762582874P | 2017-11-07 | 2017-11-07 | |
US201762596374P | 2017-12-08 | 2017-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190224A1 true JOP20190224A1 (ar) | 2019-09-26 |
Family
ID=61569356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0224A JOP20190224A1 (ar) | 2017-03-29 | 2017-06-16 | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
Country Status (33)
Country | Link |
---|---|
US (57) | US10894063B2 (ar) |
EP (6) | EP3601533B1 (ar) |
JP (5) | JP7169291B2 (ar) |
KR (1) | KR20190142342A (ar) |
CN (1) | CN110785486A (ar) |
AU (1) | AU2018243355A1 (ar) |
BR (1) | BR112019020326A2 (ar) |
CA (1) | CA3057975A1 (ar) |
CL (2) | CL2019002769A1 (ar) |
CO (1) | CO2019011995A2 (ar) |
CR (1) | CR20190487A (ar) |
CY (1) | CY1124136T1 (ar) |
DK (1) | DK3601533T3 (ar) |
EC (1) | ECSP19077884A (ar) |
ES (1) | ES2874335T3 (ar) |
HR (1) | HRP20210677T1 (ar) |
HU (1) | HUE054829T2 (ar) |
IL (2) | IL305198A (ar) |
JO (1) | JOP20190224A1 (ar) |
LT (1) | LT3601533T (ar) |
MD (1) | MD3601533T2 (ar) |
MX (1) | MX2019011768A (ar) |
NZ (1) | NZ758201A (ar) |
PE (1) | PE20191841A1 (ar) |
PH (1) | PH12019502247A1 (ar) |
PL (1) | PL3601533T3 (ar) |
PT (1) | PT3601533T (ar) |
RS (1) | RS61863B1 (ar) |
SG (1) | SG11201908994RA (ar) |
SI (1) | SI3601533T1 (ar) |
TN (1) | TN2019000273A1 (ar) |
TW (1) | TWI799402B (ar) |
WO (1) | WO2018182817A1 (ar) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105163745B (zh) | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
SG11201903331QA (en) | 2016-10-26 | 2019-05-30 | Iovance Biotherapeutics Inc | Restimulation of cryopreserved tumor infiltrating lymphocytes |
US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
WO2018226714A1 (en) * | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
BR112020009663A2 (pt) * | 2017-11-17 | 2020-11-10 | Iovance Biotherapeutics, Inc. | método para a expansão de linfócitos infiltrantes de tumor (tils) em uma população terapêutica de tils, método para o tratamento de um indivíduo com câncer, composição |
JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 末梢血からの末梢血リンパ球(pbl)の拡大培養 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
AU2019234926A1 (en) | 2018-03-15 | 2020-10-08 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
EA202092319A1 (ru) * | 2018-03-29 | 2021-03-04 | Айовэнс Байотерапьютикс, Инк. | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии |
KR20210005138A (ko) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도 |
WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
WO2020096989A1 (en) * | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
CN113272421A (zh) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途 |
MX2021004775A (es) | 2018-11-05 | 2021-06-08 | Iovance Biotherapeutics Inc | Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt). |
EP3877512A2 (en) * | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
JP2022506836A (ja) * | 2018-11-08 | 2022-01-17 | ガンマデルタ セラピューティクス リミティッド | 細胞を単離及び拡大する方法 |
EP3898949A1 (en) * | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
CA3125762A1 (en) | 2019-01-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
JPWO2021006316A1 (ar) * | 2019-07-10 | 2021-01-14 | ||
GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
JP2022544358A (ja) * | 2019-08-12 | 2022-10-18 | ベリカム ファーマシューティカルズ, インコーポレイテッド | 免疫細胞のための改良された製剤 |
JP2022546675A (ja) | 2019-08-19 | 2022-11-07 | ウニベルシテート バーゼル | 細胞治療の方法 |
WO2021061853A1 (en) * | 2019-09-24 | 2021-04-01 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
EP4048295A1 (en) * | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
EP4069237A1 (en) | 2019-12-04 | 2022-10-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
CA3161104A1 (en) * | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating lymphocytes infiltrating tumors and their use |
JP7303391B2 (ja) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | バイアス型il2ムテイン、方法、および組成物 |
JP2023524639A (ja) * | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
CA3176654A1 (en) | 2020-04-28 | 2021-11-04 | Karl PEGGS | T cell therapy |
CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
TW202208617A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途 |
GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
JP2023527531A (ja) * | 2020-05-29 | 2023-06-29 | シャンハイ ジュンセル セラピューティクス カンパニー リミテッド | 腫瘍浸潤リンパ球の種細胞培地及びその使用 |
CN111876381A (zh) * | 2020-07-22 | 2020-11-03 | 中美冠科生物技术(太仓)有限公司 | 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用 |
JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球療法によるnsclc患者の治療 |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
AU2021381496A1 (en) | 2020-11-23 | 2023-06-08 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
EP4253530A1 (en) | 2020-11-25 | 2023-10-04 | Shanghai Juncell Therapeutics Co., Ltd. | Tumor infiltration lymphocyte culture medium and application thereof |
EP4252754A1 (en) | 2020-11-25 | 2023-10-04 | Shanghai Juncell Therapeutics Co., Ltd. | Pharmaceutical composition for enhancing cell killing, and use thereof |
JP2024501452A (ja) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療 |
JP2024500403A (ja) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球によるがんの治療 |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
WO2022130015A2 (en) * | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
AU2021404204A1 (en) * | 2020-12-18 | 2023-07-06 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
EP4271791A2 (en) | 2020-12-31 | 2023-11-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
WO2022145490A1 (ja) * | 2021-01-04 | 2022-07-07 | サイアス株式会社 | iPS細胞を介する再生T細胞の製造方法 |
TW202241508A (zh) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
CA3172318A1 (en) | 2021-02-25 | 2022-09-01 | Suman Kumar VODNALA | Methods for culturing cells |
TW202300014A (zh) | 2021-03-05 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 腫瘤儲存及細胞培養組成物 |
EP4308691A1 (en) * | 2021-03-19 | 2024-01-24 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス,インコーポレイテッド | T細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
WO2022214835A1 (en) | 2021-04-09 | 2022-10-13 | Achilles Therapeutics Uk Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
JP2024515189A (ja) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用 |
JP2024515815A (ja) | 2021-04-27 | 2024-04-10 | 武田薬品工業株式会社 | 組換え抗原提示細胞 |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
DE102021002748A1 (de) | 2021-05-27 | 2022-12-01 | Zellwerk Gmbh | Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren |
CA3223030A1 (en) * | 2021-06-17 | 2022-12-22 | CBio A/S | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use |
KR20240023426A (ko) | 2021-06-22 | 2024-02-21 | 아킬레스 테라퓨틱스 유케이 리미티드 | 항원-특이적 t 세포를 생산하는 방법 |
CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
WO2023077034A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) * | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
US20240093927A1 (en) * | 2022-09-16 | 2024-03-21 | Black & Decker, Inc. | Methods and devices for controlling the temperature of a surface |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
CA2497552C (en) | 2002-09-06 | 2014-05-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
ITMI20022118A1 (it) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo. |
WO2005035728A2 (en) | 2003-10-08 | 2005-04-21 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
FR2911346B1 (fr) * | 2007-01-12 | 2012-12-07 | Ct Hospitalier Universitaire De Nantes | Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til |
EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
CA3144697A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
WO2013057500A1 (en) * | 2011-10-21 | 2013-04-25 | Cell Medica Limited | Device for the aseptic expansion of cells |
GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
EP2850175B1 (en) | 2012-05-18 | 2020-12-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2013188427A1 (en) | 2012-06-11 | 2013-12-19 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
CN105163745B (zh) | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
US20160010058A1 (en) | 2013-03-01 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of producing enriched populations of tumor-reactive t cells from tumor |
SG10201705494YA (en) | 2013-06-24 | 2017-08-30 | Wolf Wilson Mfg Corp | Closed system device and methods for gas permeable cell culture process |
EP3022294B1 (en) * | 2013-07-15 | 2019-11-20 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of preparing anti-human papillomavirus antigen t cells |
WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
KR20230085225A (ko) | 2014-03-20 | 2023-06-13 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 입양 세포 요법을 위한 종양-침윤 림프구 |
US20170044496A1 (en) | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
EP3647412A1 (en) * | 2014-04-23 | 2020-05-06 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
WO2015189357A1 (en) | 2014-06-11 | 2015-12-17 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
JP6686008B2 (ja) * | 2014-10-02 | 2020-04-22 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するt細胞受容体を単離する方法 |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
PE20191102A1 (es) | 2016-09-14 | 2019-08-23 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos |
SG11201903331QA (en) * | 2016-10-26 | 2019-05-30 | Iovance Biotherapeutics Inc | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
TW201837168A (zh) | 2017-01-06 | 2018-10-16 | 美商艾歐凡斯生物治療公司 | 以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合 |
JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
CN110832070A (zh) | 2017-05-10 | 2020-02-21 | 艾欧凡斯生物治疗公司 | 液体肿瘤来源肿瘤浸润淋巴细胞的扩增及其治疗用途 |
WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
-
2017
- 2017-06-16 JO JOP/2019/0224A patent/JOP20190224A1/ar unknown
-
2018
- 2018-01-05 BR BR112019020326A patent/BR112019020326A2/pt unknown
- 2018-01-05 EP EP18709132.7A patent/EP3601533B1/en active Active
- 2018-01-05 MX MX2019011768A patent/MX2019011768A/es unknown
- 2018-01-05 RS RS20210622A patent/RS61863B1/sr unknown
- 2018-01-05 EP EP23195819.0A patent/EP4279574A3/en active Pending
- 2018-01-05 HU HUE18709132A patent/HUE054829T2/hu unknown
- 2018-01-05 TN TNP/2019/000273A patent/TN2019000273A1/en unknown
- 2018-01-05 DK DK18709132.7T patent/DK3601533T3/da active
- 2018-01-05 EP EP20161179.5A patent/EP3730608A1/en active Pending
- 2018-01-05 MD MDE20200116T patent/MD3601533T2/ro unknown
- 2018-01-05 JP JP2019553050A patent/JP7169291B2/ja active Active
- 2018-01-05 SI SI201830278T patent/SI3601533T1/sl unknown
- 2018-01-05 NZ NZ758201A patent/NZ758201A/en unknown
- 2018-01-05 PL PL18709132T patent/PL3601533T3/pl unknown
- 2018-01-05 EP EP21175134.2A patent/EP3910055A1/en active Pending
- 2018-01-05 KR KR1020197031407A patent/KR20190142342A/ko not_active Application Discontinuation
- 2018-01-05 CR CR20190487A patent/CR20190487A/es unknown
- 2018-01-05 PE PE2019001976A patent/PE20191841A1/es unknown
- 2018-01-05 WO PCT/US2018/012633 patent/WO2018182817A1/en active Application Filing
- 2018-01-05 LT LTEP18709132.7T patent/LT3601533T/lt unknown
- 2018-01-05 AU AU2018243355A patent/AU2018243355A1/en active Pending
- 2018-01-05 ES ES18709132T patent/ES2874335T3/es active Active
- 2018-01-05 CA CA3057975A patent/CA3057975A1/en active Pending
- 2018-01-05 TW TW107100568A patent/TWI799402B/zh active
- 2018-01-05 PT PT187091327T patent/PT3601533T/pt unknown
- 2018-01-05 CN CN201880035181.8A patent/CN110785486A/zh active Pending
- 2018-01-05 US US15/863,634 patent/US10894063B2/en active Active
- 2018-01-05 IL IL305198A patent/IL305198A/en unknown
- 2018-01-05 EP EP20183493.4A patent/EP3766964A1/en active Pending
- 2018-01-05 SG SG11201908994R patent/SG11201908994RA/en unknown
- 2018-01-05 EP EP20161276.9A patent/EP3722415A1/en active Pending
- 2018-01-18 US US15/874,718 patent/US10166257B2/en active Active
- 2018-02-08 US US15/892,311 patent/US10130659B2/en active Active
- 2018-03-29 US US15/940,901 patent/US10918666B2/en active Active
- 2018-06-29 JP JP2020552291A patent/JP2021519582A/ja active Pending
- 2018-06-29 US US17/041,305 patent/US20210079348A1/en active Pending
- 2018-09-19 US US16/136,147 patent/US10272113B2/en active Active
- 2018-09-19 US US16/136,157 patent/US10420799B2/en active Active
- 2018-11-15 US US16/192,707 patent/US10537595B2/en active Active
- 2018-11-27 US US16/201,957 patent/US10398734B2/en active Active
- 2018-11-28 US US16/203,467 patent/US10463697B2/en active Active
- 2018-11-28 US US16/203,478 patent/US10363273B2/en active Active
-
2019
- 2019-05-29 US US16/425,778 patent/US10646517B2/en active Active
- 2019-05-29 US US16/425,767 patent/US10695372B2/en active Active
- 2019-05-29 US US16/425,746 patent/US10639330B2/en active Active
- 2019-09-23 IL IL26954319A patent/IL269543A/en unknown
- 2019-09-27 PH PH12019502247A patent/PH12019502247A1/en unknown
- 2019-09-27 CL CL2019002769A patent/CL2019002769A1/es unknown
- 2019-10-28 CO CONC2019/0011995A patent/CO2019011995A2/es unknown
- 2019-10-29 EC ECSENADI201977884A patent/ECSP19077884A/es unknown
-
2020
- 2020-01-17 US US16/746,416 patent/US10653723B1/en active Active
- 2020-04-14 US US16/848,442 patent/US10933094B2/en active Active
- 2020-04-14 US US16/848,361 patent/US10905718B2/en active Active
- 2020-04-14 US US16/848,474 patent/US10946045B2/en active Active
- 2020-04-14 US US16/848,454 patent/US10946044B2/en active Active
- 2020-04-14 US US16/848,426 patent/US10953047B2/en active Active
- 2020-04-14 US US16/848,386 patent/US10953046B2/en active Active
- 2020-05-20 US US16/879,711 patent/US10925900B2/en active Active
- 2020-10-22 CL CL2020002737A patent/CL2020002737A1/es unknown
- 2020-12-02 US US17/110,207 patent/US11083752B2/en active Active
- 2020-12-02 US US17/110,179 patent/US20210100842A1/en active Pending
- 2020-12-18 US US17/127,840 patent/US11052116B2/en active Active
- 2020-12-18 US US17/127,795 patent/US11052115B2/en active Active
- 2020-12-18 US US17/127,790 patent/US11007226B2/en active Active
- 2020-12-18 US US17/127,768 patent/US11007225B1/en active Active
-
2021
- 2021-01-12 US US17/147,412 patent/US20210214685A1/en active Pending
- 2021-01-12 US US17/147,090 patent/US11040070B2/en active Active
- 2021-01-12 US US17/147,096 patent/US20210128625A1/en active Pending
- 2021-01-12 US US17/147,080 patent/US20210128623A1/en active Pending
- 2021-01-12 US US17/147,073 patent/US11013770B1/en active Active
- 2021-01-13 US US17/148,508 patent/US11168304B2/en active Active
- 2021-01-13 US US17/148,475 patent/US11168303B2/en active Active
- 2021-04-28 HR HRP20210677TT patent/HRP20210677T1/hr unknown
- 2021-05-14 CY CY20211100416T patent/CY1124136T1/el unknown
- 2021-05-20 US US17/326,088 patent/US11202803B1/en active Active
- 2021-07-22 US US17/383,280 patent/US11304979B2/en active Active
- 2021-07-22 US US17/383,272 patent/US11202804B2/en active Active
- 2021-07-22 US US17/383,276 patent/US11273180B2/en active Active
- 2021-07-22 US US17/382,831 patent/US11241456B2/en active Active
- 2021-09-21 US US17/480,587 patent/US11344579B2/en active Active
- 2021-09-21 US US17/480,596 patent/US11337998B2/en active Active
- 2021-09-21 US US17/480,534 patent/US11291687B2/en active Active
- 2021-09-21 US US17/480,525 patent/US11273181B2/en active Active
-
2022
- 2022-07-01 US US17/856,806 patent/US20230133298A1/en active Pending
- 2022-07-01 US US17/856,793 patent/US20230015649A1/en active Pending
- 2022-07-01 US US17/856,800 patent/US11517592B1/en active Active
- 2022-08-03 US US17/817,247 patent/US20220387497A1/en active Pending
- 2022-08-03 US US17/817,207 patent/US20220387494A1/en active Pending
- 2022-08-03 US US17/817,279 patent/US11541077B2/en active Active
- 2022-08-03 US US17/817,281 patent/US11529372B1/en active Active
- 2022-08-03 US US17/817,217 patent/US20220395533A1/en active Pending
- 2022-08-03 US US17/817,232 patent/US20220387496A1/en active Granted
- 2022-08-03 US US17/817,239 patent/US20230012086A1/en active Pending
- 2022-08-03 US US17/817,273 patent/US20230045899A1/en active Pending
- 2022-08-03 US US17/817,226 patent/US20220387495A1/en active Pending
- 2022-08-03 US US17/817,276 patent/US20220387498A1/en active Pending
- 2022-10-28 JP JP2022173683A patent/JP2023012511A/ja active Pending
- 2022-10-28 JP JP2022173684A patent/JP2023011778A/ja active Pending
- 2022-10-28 JP JP2022173682A patent/JP2023012510A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502247A1 (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
PH12021551033A1 (en) | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | |
MX2020010264A (es) | Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia. | |
MX2020011134A (es) | Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia. | |
CA3155727A1 (en) | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
WO2021226061A8 (en) | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | |
PH12017500680A1 (en) | Compositions and methods of use for treating metabolic disorders | |
MY192917A (en) | Compositions and methods of use for treating metabolic disorders | |
SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
MD4733C1 (ro) | Anticorpi anti-TIGIT | |
MY187486A (en) | Cysteine protease | |
MX2017008813A (es) | Polvo de coleopteros. | |
MY188696A (en) | Cysteine protease | |
MX2015009991A (es) | Composiciones y metodos. | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
MX2017015424A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
MX2019000677A (es) | Células miméticas de células b. | |
MX2017001566A (es) | Terapias antibioticas peptidicas derivadas del bufalo de agua. | |
AR126650A2 (es) | Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia | |
EA202191275A1 (ru) | Способы получения инфильтрующих опухоли лимфоцитов и варианты их применения в иммунотерапии | |
AR110733A1 (es) | Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia | |
WO2023004074A3 (en) | Method for cryopreservation of solid tumor fragments | |
EA201992293A1 (ru) | Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии | |
UA112357C2 (uk) | Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи |